Nanoliposomal irinotecan
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-NAL-IRI |
|---|---|
| Type | Drug |
| Aliases | Irinotecan liposomeOnivydenal-IRIpegylated liposomal irinotecan |
| Status | reviewed 2026-05-07 |
| Diseases | DIS-PDAC |
| Sources | SRC-ESMO-PANCREATIC-2024 SRC-NAPOLI1-WANG-GILLAM-2016 SRC-NCCN-PANCREATIC-2025 |
Drug Facts
| Class | Liposomal topoisomerase I inhibitor |
|---|---|
| Mechanism | Liposomal irinotecan formulation that delivers irinotecan, a prodrug converted to SN-38, which inhibits topoisomerase I and causes replication- associated DNA damage. |
| Typical dosing | Post-gemcitabine metastatic pancreatic adenocarcinoma: 70 mg/m2 free base IV over 90 minutes every 2 weeks with leucovorin and 46-hour infusional fluorouracil. Dose adjust for toxicity and relevant pharmacogenomic risk. |
| Ukraine registered | False |
| NSZU reimbursed | False |
Warnings
- Severe neutropenia
- Severe diarrhea
Notes
Thin drug entity added to resolve REG-NAL-IRI-5FU-LV-PDAC component references. Do not treat as interchangeable with conventional irinotecan.
Used By
Regimens
REG-NAL-IRI-5FU-LV-PDAC- Nal-IRI + 5-FU/LV (PDAC, 2L nanoliposomal irinotecan)